KR20240115910A - 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법 - Google Patents

항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법 Download PDF

Info

Publication number
KR20240115910A
KR20240115910A KR1020247023419A KR20247023419A KR20240115910A KR 20240115910 A KR20240115910 A KR 20240115910A KR 1020247023419 A KR1020247023419 A KR 1020247023419A KR 20247023419 A KR20247023419 A KR 20247023419A KR 20240115910 A KR20240115910 A KR 20240115910A
Authority
KR
South Korea
Prior art keywords
antibody
fragment
administered
tau
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023419A
Other languages
English (en)
Korean (ko)
Inventor
라리사 레이더만
진 저우
린 크레이머
마이클 이리재리
팔라비 사츠데브
쇼바 다다
데이비드 리
크리스틴 와일드스미스
포 아세베스 발도
서밋 라왈
아키히코 고야마
채드 스완슨
미치오 가네키요
준 캐플로
데이비드 버벨
이샤니 랜드리
세이이치 하야토
로버트 고든
랜달 베이트먼
에릭 맥데이드
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
워싱톤 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000937 external-priority patent/WO2023111618A1/en
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤, 워싱톤 유니버시티 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20240115910A publication Critical patent/KR20240115910A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine (AREA)
KR1020247023419A 2021-12-17 2022-11-08 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법 Pending KR20240115910A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163291315P 2021-12-17 2021-12-17
US63/291,315 2021-12-17
IBPCT/IB2021/000937 2021-12-17
PCT/IB2021/000937 WO2023111618A1 (en) 2021-12-17 2021-12-17 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
PCT/US2022/079509 WO2023114586A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Publications (1)

Publication Number Publication Date
KR20240115910A true KR20240115910A (ko) 2024-07-26

Family

ID=84387973

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023419A Pending KR20240115910A (ko) 2021-12-17 2022-11-08 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법

Country Status (8)

Country Link
US (1) US20250051427A1 (https=)
EP (1) EP4448005A1 (https=)
JP (1) JP2024547001A (https=)
KR (1) KR20240115910A (https=)
AU (1) AU2022410770A1 (https=)
CA (1) CA3242280A1 (https=)
MX (1) MX2024007288A (https=)
WO (1) WO2023114586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN112187401B (zh) 2019-07-03 2022-06-14 华为技术有限公司 多时间单元传输方法及相关装置
US11877315B2 (en) 2020-09-15 2024-01-16 Qualcomm Incorporated Wireless device digital beamforming capability indication

Also Published As

Publication number Publication date
EP4448005A1 (en) 2024-10-23
WO2023114586A1 (en) 2023-06-22
MX2024007288A (es) 2024-06-28
AU2022410770A1 (en) 2024-06-13
CA3242280A1 (en) 2023-06-22
JP2024547001A (ja) 2024-12-26
US20250051427A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
WO2021081101A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
TW202317192A (zh) 用於阿茲海默氏症治療的生物標記物
WO2023111618A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
JP2024540226A (ja) 抗タウ抗体組成物、投薬形態、及び方法
KR20240115910A (ko) 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법
CN118765204A (zh) 抗trem2抗体的使用方法
TW202339794A (zh) 使用ｐ—ｔａｕ１８１水平之治療方法
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
KR20240053620A (ko) 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법
TW202434629A (zh) 以抗類澱粉β (ABETA)抗體治療神經病症之方法
CA3135181A1 (en) Fusion constructs and uses thereof
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
US20250361292A1 (en) Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
TW202541846A (zh) 以抗類澱粉蛋白β (ABETA)抗體治療神經病症之方法
WO2026025002A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000